Breast Cancer

A recent analysis identified disparities in the start of breast cancer treatment and the duration of treatment in Black women compared with White women.

Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

This week, the top managed care news included COVID-19 delays in breast cancer surgery; targeted therapies associated with decreased mortality risk for non–small cell lung cancer; an inside look at a patient’s perspective of early-onset Parkinson disease.

A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.

Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.

A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.

Aspirin is a known anti-inflammatory agent, but few studies have investigated its use among African American women to reduce the risk of breast cancer.

A study out of Scotland has linked levels of 2 short-chain fatty acids in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy.

Long-term study results show which mechanisms of early-onset puberty in adolescent girls may predispose them to a greater risk of developing breast cancer.

Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.

With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.